Digest Network Come funziona
Network
/
Società
Sc
Non verificato

Scribe Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaIndustriaSalute

7 comunicati stampa

Guarda tutti i comunicati
18/06/2026
Mercato del lavoro
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/05/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0
21/05/2026
Industria
Biotecnologia
Salute
Medicina - Varie
Cardiologia
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/05/2026
Eventi
Industria
Cardiologia
Biotecnologia
Tecnica
Salute
Farmaceutica
Scienza
Software
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/04/2026
Eventi
Salute
Biotecnologia
Scienza
Farmaceutica
Cardiologia
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/02/2026
Industria
Salute
Biotecnologia
Farmaceutica
Cardiologia
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/01/2026
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0